General Information of Drug (ID: DM5UNBW)

Drug Name
4-Phenylimidazole Drug Info
Synonyms
4-Phenylimidazole; 670-95-1; 4-PHENYL-1H-IMIDAZOLE; 5-Phenyl-1H-imidazole; 4(5)-Phenylimidazole; 1H-Imidazole, 4-phenyl-; Imidazole, 4-phenyl-; 5-phenylimidazole; 4-PHENYL IMIDAZOLE; CHEMBL14145; XHLKOHSAWQPOFO-UHFFFAOYSA-N; MFCD00005197; NSC-195337; F1918-0054; PIM; 4-phenyl-1h-imidazol; 4-phenyl-imidazole; EINECS 211-580-1; PubChem7224; NSC 195337; ACMC-209nxp; 4-phenylimidazole, 4-PI; 4-Phenylimidazole, 97%; 1H-Imidazole, 5-phenyl-; AC1L2C7W; AC1Q4YD1; SCHEMBL37563; KSC696A2D; Imidazole, 4-phenyl- (8CI); AMBZ0133; CTK5J6021
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
69590
CAS Number
CAS 670-95-1
TTD Drug ID
DM5UNBW

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
L-Tryptophan DMIBH7M Depression 6A70-6A7Z Approved [2]
Avastin+/-Tarceva DMA86FL Non-small-cell lung cancer 2C25.Y Phase 3 [3]
BMS-986205 DM3MAYQ Melanoma 2C30 Phase 3 [4]
INCB24360 DMIJGT9 Urothelial carcinoma 2C92.0 Phase 3 [5]
NLG8189 DM0798Z Melanoma 2C30 Phase 2/3 [4]
DN1406131 DMQFX8R Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
HTI-1090 DMI4TEC Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
KHK2455 DMLSUQ8 Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
LY3381916 DMONZ1L Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
PF-06840003 DMOX6EJ Glioma 2A00.0 Phase 1 [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Indoleamine 2,3-dioxygenase 1 (IDO1) TTZJYKH I23O1_HUMAN Inhibitor [1]

References

1 Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase. J Med Chem. 2008 Aug 28;51(16):4968-77.
2 Interactions between nitric oxide and indoleamine 2,3-dioxygenase. Biochemistry. 2006 Jul 18;45(28):8527-38.
3 Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J Med Chem. 2008 Mar 27;51(6):1706-18.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Incyte. Product Development Pipeline.
6 ClinicalTrials.gov (NCT03641794) Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers. U.S. National Institutes of Health.
7 Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation. J Enzyme Inhib Med Chem. 2019 Dec;34(1):250-263.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)